Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory BoardNewsfile Corp • 01/19/22
Cardiol Therapeutics raises US$50M to advance research and clinical development initiativesProactive Investors • 11/05/21
Cardiol Therapeutics receives Health Canada approval for Phase II trial of CardiolRxProactive Investors • 10/25/21
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute MyocarditisNewsfile Corp • 10/25/21
Cardiol Therapeutics announces expansion of LANCER Phase II/III trial to three new countriesProactive Investors • 10/18/21
Cardiol Therapeutics announces appointment of Michael J. Willner to its board of directors, effective immediatelyProactive Investors • 09/07/21
Cardiol Therapeutics is commercializing its THC-free cannabidiol formulation to treat heart diseaseProactive Investors • 08/26/21
Cardiol Therapeutics wins FDA approval for clinical trial of CardiolRx to treat patients with acute myocarditisProactive Investors • 08/24/21
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute MyocarditisNewsfile Corp • 08/24/21
Cardiol Therapeutics receives final approval to list its common shares on NASDAQ from August 10, 2021Proactive Investors • 08/09/21